Similarly aiming to enhance existing cancer therapies, Hagiwara et al. investigated how statins might augment the effects of mammalian target of rapamycin (mTOR) inhibitors in renal cell carcinoma. This evidence concerns the gene MTOR and renal cell carcinoma.